Clinical trial
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive…
NCT00182806 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00182806 |
|---|---|
| Title | Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer |
| Official title | Phase II Study of Irinotecan Followed by Gemcitabine in NSCLC Following Failure of Platinum Based Therapy |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, irinotecan hydrochloride |
| Enrollment | 38 |
| Start date | Sep 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Jul 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: